The Contribution of Inflammation and Insulin Resistance to Intermittent Claudication

NCT00153166 Phase 2/Phase 3 COMPLETED Results posted

This trial will test the hypothesis that inflammation and insulin resistance contribute to reduced walking distance in subjects with intermittent claudication by impairing vascular reactivity and skeletal muscle metabolic function.

Details

Lead sponsor	Brigham and Women's Hospital
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	76
Start date	2004-01
Completion	2011-12

Conditions

• Arterial Occlusive Disease
• Intermittent Claudication
• Insulin Resistance

Interventions

• atorvastatin and pioglitazone
• atorvastatin/placebo
• pioglitazone/placebo
• placebo/placebo

Primary outcomes

• Lower Extremity Skeletal Muscle Glucose Uptake — 60 minutes
  Net calf skeletal muscle glucose uptake determined by Patlak modeling.

Countries

United States